JBIO earnings date and last-quarter result: next report 2026-08-12, last quarter miss, P/E -6.80. Updated 2026-07-23.
Jade Biosciences (JBIO) Research Hub
Jade Biosciences (JBIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 14.5 USD (-0.62%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -6.80, market cap 0.64B. This hub links to the full technical, earnings and options research available for JBIO.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 14.5 USD (-0.62%) |
| 52-week range | 12.847 USD – 24.94 USD |
| Trend regime | Range |
| 14-day RSI | 61.2 (Bullish) |
| Trailing P/E | -6.80 |
| Market cap | 0.64B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for JBIO
Covered Call on JBIO: how it works, illustrative setup around the real 14.5 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on JBIO: how it works, illustrative setup around the real 14.5 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on JBIO: how it works, illustrative setup around the real 14.5 USD price, max profit/loss, breakeven and when to use it. Educational.
JBIO technical analysis: range, last 14.5 USD, RSI 61.2, 52w range 12.847 USD–24.94 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is JBIO in?
Jade Biosciences (JBIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is JBIO in an uptrend or downtrend?
As of 2026-10-26, JBIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is JBIO's trailing P/E ratio?
JBIO's trailing P/E is -6.80, with a market cap of 0.64B. See the earnings research page for full valuation detail.
When does JBIO next report earnings?
JBIO is next scheduled to report earnings on 2026-08-12.